SOLIRIS®

Soliris® (Eculizumab) is a monoclonal antibody in the category of immunosuppressive drugs used for the treatment of hemolytic blood disorders. SOLIRIS® works by selectively slowing down the complement system in the human body.

Soliris® is manufactured by Alexion.

Administration and Dosage:

Recommended administration of SOLIRIS® is an intravenous infusion weekly for 4 weeks following by the 5th dose 1 week later and then every 2 weeks thereafter.

Common Side Effects:

The more common side effects of SOLIRIS® include serious allergic reactions.

More information:

Please read the full Prescribing Information for SOLIRIS® and discuss any questions you have with your doctor.

Indication:

Soliris® is indicated to treat:

  • Paroxysmal Nocturnal Hemoglobinuria

  • Atypical Hemolytic Uremic Syndrome

  • Generalized Myasthenia Gravis

  • Neuromyelitis Optica Spectrum Disorder

Contact Us

Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!

Check our Privacy Practice